These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21820091)

  • 1. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
    Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
    Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid improves bone mineral density in pediatric spinal cord injury.
    Ooi HL; Briody J; McQuade M; Munns CF
    J Bone Miner Res; 2012 Jul; 27(7):1536-40. PubMed ID: 22437628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
    N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture risk and zoledronic acid therapy in men with osteoporosis.
    Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
    N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 14. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 15. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.